| Identification | Back Directory | [Name]
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- | [CAS]
76588-87-9 | [Synonyms]
Yadanzigan
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- | [Molecular Formula]
C26H38O14 | [MOL File]
76588-87-9.mol | [Molecular Weight]
574.57 |
| Hazard Information | Back Directory | [Uses]
Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice[1]. | [in vivo]
Yadanzigan (5 mg/kg, 10 mg/kg; i.v.; dose for 3 times) prevents LPS-induced acute lung injury in mouse model[1]. | Animal Model: | Male BABL/C mice (18-22 g)[1] | | Dosage: | 5 mg/kg, 10 mg/kg | | Administration: | Intravenous injection; dose at 2 h prior to and 6 h, 12 h after LPS induction
| | Result: | Reduced LPS-induced infiltration of inflammatory cells and cytokine levels, such as TNF-α and IL-6. Inhibited NLRP3 inflammasome activation in lung tissue.
Resulted significantly greater survival rate. |
| [IC 50]
NLRP3 inflammasome | [References]
[1] Cui Y, et al. Yadanzigan, a quassinoid glucoside, attenuates NLRP3 inflammasome activation to prevent LPS-induced acute lung injury. Authorea Preprints, 2020. |
| Spectrum Detail | Back Directory | [Spectrum Detail]
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)-(76588-87-9)1HNMR
|
|
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|